［1］HSIEH JJ,PURDUE MP,SIGNORETTI S,et al.Renal cell carcinoma［J］.Nat Rev Dis Primers,2017,3:17009.
［2］SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］.CA:A Cancer Journal for Clinicians,2021,71(3):209-249.
［3］CHEN WQ,ZHENG RS,BAADE PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［4］PIRILLO A,CASULA M,OLMASTRONI E,et al.Global epidemiology of dyslipidaemias［J］.Nat Rev Cardiol,2021,18(10):689-700.
［5］诸骏仁,高润霖,赵水平,等.中国成人血脂异常防治指南(2016年修订版)［J］.中华健康管理学杂志,2017,11（1):7-28.
ZHU JR,GAO RL,ZHAO SP,et al.Chinese guidelines for the prevention and treatment of dyslipidemia in adults（2016 revision)［J］.Chinese Journal of Health Management,2017,11（1):7-28.
［6］刘坤,滕立臣.肾癌发生发展及转移中脂肪代谢的最新研究进展［J］.现代肿瘤医学,2020,28(23):4176-4180.
LIU K,TENG LC.Lipid metabolism in the development and metastasis of renal cell carcinoma［J］.Modern Oncology,2020,28(23):4176-4180.
［7］ZHANG C,YU L,XU T,et al.Association of dyslipidemia with renal cell carcinoma:A 1∶2 matched case-control study［J］.PLoS One,2013,8(3):e59796.
［8］ZHANG G,ZHU Y,LUO L,et al.Prevalence of dyslipidaemia in patients with renal cell carcinoma:A case-control study in China［J］.BJU Int,2014,113(5b):e75-81.
［9］LI B,HUANG DE,ZHENG H,et al.Preoperative serum total cholesterol is a predictor of prognosis in patients with renal cell carcinoma:A Meta-analysis of observational studies［J］.Int Braz J Urol,2020,46(2):158-168.
［10］HERAVI G,YAZDANPANAH O,PODGORSKI I,et al.Lipid metabolism reprogramming in renal cell carcinoma［J］.Cancer Metastasis Rev,2022,41(1):17-31.
［11］BOBULESCU IA,POP LM,MANI C,et al.Renal lipid metabolism abnormalities in obesity and clear cell renal cell carcinoma［J］.Metabolites,2021,11(9):608.
［12］YANG H,ZHANG X,LIU F,et al.SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-κB signaling［J］.Biochem Biophys Res Commun,2018,495(1):1383-1388.
［13］LEE JH,JEON YG,LEE K,et al.RNF20 suppresses tumorigenesis by inhibiting the SREBP1c-PTTG1 axis in kidney cancer［J］.Mol Cell Biol,2017,37(22):e00265-17.
［14］XU W,HU X,ANWAIER A,et al.Fatty acid synthase correlates with prognosis-related abdominal adipose distribution and metabolic disorders of clear cell renal cell carcinoma［J］.Front Mol Biosci,2020,7:610229.
［15］YUAN Y,YANG X,LI Y,et al.Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma［J］.Pathol Res Pract,2020,216(11):153227.
［16］BACIGALUPA ZA,RATHMELL WK.Beyond glycolysis:Hypoxia signaling as a master regulator of alternative metabolic pathways and the implications in clear cell renal cell carcinoma［J］.Cancer Lett,2020,489:19-28.
［17］ZHANG H,YU L,CHEN J,et al.Role of metabolic reprogramming of long non-coding RNA in clear cell renal cell carcinoma［J］.J Cancer,2022,13(2):691-705.
［18］WANG S,WEI X,JI C,et al.Adipogenic transdifferentiation and regulatory factors promote the progression and the immunotherapy response of renal cell carcinoma:Insights from integrative analysis［J］.Front Oncol,2022,12:781932.
［19］DU W,ZHANG L,BRETT-MORRIS A,et al.HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism［J］.Nat Commun,2017,8(1):1769.
［20］QIU B,ACKERMAN D,SANCHEZ DJ,et al.HIF2α-dependent lipid storage promotes endoplasmic reticulum homeostasis in clear-cell renal cell carcinoma［J］.Cancer Discov,2015,5(6):652-667.
［21］HAYES JD,DINKOVA-KOSTOVA AT,TEW KD,et al.Oxidative stress in cancer［J］.Cancer Cell,2020,38(2):167-197.
［22］田美娟,李雨遥,罗长琴,等.肾透明细胞癌中氧化应激蛋白的表达［J］.细胞与分子免疫学杂志,2012,28（8):851-855.
TIAN MJ,LI YY,LUO CQ,et al.Expression of oxidative stress proteins in the clear-cell renal cell carcinoma［J］.Chinese Journal of Cellular and Molecular Immunology,2012,28（8):851-855.
［23］PAVLOVIC I,PEJIC S,RADOJEVIC-SKODRIC S,et al.The effect of antioxidant status on overall survival in renal cell carcinoma［J］.Arch Med Sci,2020,16(1):94-101.
［24］WU G,ZHANG Z,TANG Q,et al.Study of FABP's interactome and detecting new molecular targets in clear cell renal cell carcinoma［J］.J Cell Physiol,2020,235(4):3776-3789.
［25］VAN HM,GARMO H,HAMMAR N,et al.The interplay between lipid profiles,glucose,BMI and risk of kidney cancer in the Swedish AMORIS study［J］.Int J Cancer,2012,130(9):2118-2128.
［26］HAGGSTROM C,RAPP K,STOCKS T,et al.Metabolic factors associated with risk of renal cell carcinoma［J］.PLoS One,2013,8(2):e57475.
［27］KITAHARA CM,BERRINGTON DE GONZALEZ A,FREEDMAN ND,et al.Total cholesterol and cancer risk in a large prospective study in Korea［J］.J Clin Oncol,2011,29(12):1592-1598.
［28］ULMER H,BORENA W,RAPP K,et al.Serum triglyceride concentrations and cancer risk in a large cohort study in Austria［J］.Br J Cancer,2009,101(7):1202-1206.
［29］AHN J,LIM U,WEINSTEIN SJ,et al.Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer［J］.Cancer Epidemiol Biomarkers Prev,2009,18(11):2814-2821.
［30］HADDAD AQ,JIANG L,CADEDDU JA,et al.Statin use and serum lipid levels are associated with survival outcomes after surgery for renal cell carcinoma［J］.Urology,2015,86(6):1146-1152.
［31］杜依青,刘慧鑫,刘春雷,等.代谢相关因素与肾细胞癌分级、分期的相关研究［J］.北京大学学报(医学版),2016,48（4):612-617.
DU YQ,LIU HX,LIU CL,et al.Analysis of metabolic factors and relevance with the grade and stage in patients with renal cell carcinoma［J］.Journal of Peking University(Health Sciences),2016,48（4):612-617.
［32］HAO B,PENG X,BI B,et al.Preoperative serum high-density lipoprotein cholesterol as a predictor of poor survival in patients with clear cell renal cell cancer［J］.Int J Biol Markers,2019,34(2):168-175.
［33］殷俊.低密度脂蛋白胆固醇在肾透明细胞癌患者中的预后价值［D］.苏州：苏州大学,2019.
YIN J.Prognostic value of preoperative serum low-density lipoprotein cholesterol in patients with clear cell renal cell cancer［D］.Suzhou:Soochow University,2019.
［34］LEE H,JEONG CW,KWAK C,et al.Preoperative cholesterol level is associated with worse pathological outcomes and postoperative survival in localized renal cell carcinoma patients:A propensity score-matched study［J］.Clin Genitourin Cancer,2017,15(6):e935-e941.
［35］GUO S,HE X,CHEN Q,et al.The effect of preoperative apolipoprotein A-I on the prognosis of surgical renal cell carcinoma:A retrospective large sample study［J］.Medicine（Baltimore),2016,95(12):e3147.
［36］徐会敏,娄阁.卵巢肿瘤与血脂水平相关性分析及他汀类药物在卵巢癌中应用的研究进展［J］.现代肿瘤医学,2020,28（4):659-662.
XU HM,LOU G.Advances in research on correlation between ovarian neoplasms and blood lipid levels and application of statins in ovarian cancer［J］.Modern Oncology,2020,28（4):659-662.
［37］JUAREZ D,FRUMAN DA.Targeting the mevalonate pathway in cancer［J］.Trends Cancer,2021,7(6):525-540.
［38］HAMILTON RJ,MORILLA D,CABRERA F,et al.The association between statin medication and progression after surgery for localized renal cell carcinoma［J］.J Uro,2014,191(4):914-919.
［39］WU P,XIANG T,WANG J,et al.Statin use and the overall survival of renal cell carcinoma:A meta-analysis［J］.Clin Invest Med,2020,43(4):E17-23.